Proactive Investors - Run By Investors For Investors

Cancer drug payment nudges Sareum Holdings into maiden profit

Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company's posted a maiden profit after receiving the first payments from licensing lead product, a Chk1 inhibitor cancer candidate, to Sierra Oncology.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full SAR profile View Profile

Sareum Holdings Plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use